Liquidity Check
What does Elevance Health's latest financial snapshot show?
Mixed. The strongest factor is liquidity and scale, while the main concern is medical cost pressure and CMS-related GAAP EPS risk.
Using Q1 2026 as the latest comparable period, this snapshot blends growth, profitability, cash generation, balance-sheet capacity, and capital efficiency. For broader strategy context, see Mission Statement, Vision, & Core Values (2026) of Elevance Health Inc. (ELV).
The metric that deserves deeper analysis first is Revenue Growth, because it frames whether Elevance Health’s scale is still expanding fast enough to offset cost pressure.
Revenue Quality
Is Elevance Health's revenue growth producing quality earnings?
Mixed. Revenue is still recurring and broad, but earnings quality is less convincing because rising medical costs, Medicaid pressure, and Carelon reinvestment are weakening conversion from revenue growth into operating income and net income.
Growth quantity is not the same as growth quality. Investors compare revenue durability with operating income, net income, and EPS across compatible annual periods because revenue can rise while margins fall, and the link matters even more for a managed care business such as Elevance Health Inc. (ELV): History, Ownership, Mission, How It Works & Makes Money.
| Measure | Latest Period | Previous Period | Quality Test | Investor Meaning |
|---|---|---|---|---|
| Revenue | Full Year 2025 Operating Revenue of $1976B, an increase of 1300% year-over-year | Full Year 2024 Operating Revenue | Unclear; growth source not fully separated, but membership and segment mix suggest recurring insurance and services demand | Recurring demand supports repeatability, but the scale of growth needs margin support to prove quality |
| Operating Income | Q1 2026 Operating Income of $266B | Q1 2025 Operating Income | Growth was slower than revenue because benefit costs and reinvestment pressured conversion | Operating leverage is weak, so revenue growth is not fully flowing through |
| Net Income | Q1 2026 Net Income of $176B | Q1 2025 Net Income | Supported by earnings, but adjusted results were helped by approximately $100 per share of non-recurring investment income | Final earnings are less durable than revenue because one-time items lifted per-share results |
| Diluted EPS | Q1 2026 EPS Diluted of $800 | Q1 2025 EPS Diluted | Share-count impact is not provided; adjusted support was stronger than GAAP support | Shareholders did not get a clean one-to-one read-through from revenue growth |
How durable is Elevance Health's revenue?
Revenue durability looks fairly strong because membership is broad and Carelon adds diversification, but the biggest limitation is mix pressure from Medicare Advantage and Medicaid, which makes earnings more exposed to medical-cost trends.
- Demand Quality: Revenue is recurring through health plan premiums and services, so visibility is decent, but government-program exposure adds volatility.
- Pricing and Volume: Health Benefits revenue rose with premium yield, while Carelon growth reflected services expansion; the split beyond that is unavailable.
- Diversification: Total medical membership of 454M and Carelon revenue of $180B show diversification, but Medicaid and Medicare Advantage remain important concentration points.
That mix matters because durable revenue only becomes durable cash generation when margins and claims costs stay under control.
Cash Conversion
Are Elevance Health's profits turning into cash?
Not fully yet. Elevance Health’s margins were pressured in Q1 2026 and full-year 2025, while the supplied cash-flow data only shows growth rates, not cash dollar amounts, so reported earnings cannot be fully confirmed against operating and free cash flow here.
Gross margin shows how much remains after direct claims and service costs, operating margin shows what is left after operating expenses, and net margin shows final profit after interest and taxes. Elevance Health reported $176B net income for 2026-03-31, but margin pressure from Medicaid costs and state rate timing matters more for cash quality than net income alone. For related investor context, see Exploring Elevance Health Inc. (ELV) Investor Profile: Who's Buying and Why?
| Measure | Latest Period | Previous Period | Verified Driver | Investor Meaning |
|---|---|---|---|---|
| Gross Margin | Not supplied for Q1 2026 | Not supplied for Q1 2025 | Benefit Expense Ratio was 8680% in Q1 2026, up 40 basis points from Q1 2025. | Higher medical cost pressure implies weaker product economics and less room for underwriting profit. |
| Operating Margin | Not supplied for Q1 2026 | Not supplied for Q1 2025 | Operating expenses were $644B against revenue of $5018B, but no margin ratio was supplied. | Scale cannot be read cleanly from the data here, though cost pressure can still weigh on efficiency. |
| Net Margin | Not supplied for Q1 2026 | Not supplied for Q1 2025 | Net income was $176B; $35,700M interest expense, $54,400M income tax expense, and a $935M CMS accrual affected GAAP earnings. | Final profitability includes non-operating and unusual items, so GAAP earnings may overstate recurring strength. |
| Operating Cash Flow | Operating Cash Flow Growth of 505714% for 2026-03-31 | Previous period not supplied | Receivables Growth of 4958% and Days in Claims Payable of 466 days, up from 413 days at year-end 2025, point to working-capital movement. | Cash conversion may be improving, but the dollar amount is not disclosed here. |
| Free Cash Flow | Free Cash Flow Growth of 206029% for 2026-03-31 | Previous period not supplied | Growth Capital Expenditure of 1980% shows reinvestment pressure. | Free cash after investment is harder to verify without the underlying dollar value. |
What most affects Elevance Health's cash conversion?
The biggest verified driver is working capital, especially receivables growth and the rise in days in claims payable, with margin pressure from Medicaid costs also shaping cash conversion. The pattern looks partly structural, not just temporary.
- Main Driver: Claims payable and receivables movement are the clearest cash drivers; that looks tied to operations and timing, not a one-off.
- Evidence Gap: The supplied data does not show operating cash flow dollars or free cash flow dollars.
- Metric to Monitor: Watch operating cash flow, claims payable days, and the benefit expense ratio.
Balance Sheet Capacity
Does Elevance Health have enough balance-sheet capacity to support its obligations and investment needs?
Mixed. Elevance Health has strong near-term liquidity, but it also uses meaningful debt, so the main protection is its large cash and short-term investment base, while the main financing concern is claims timing and the need to keep funding flexibility under regulated capital demands.
Cash alone is not enough for an insurer, because claims timing, premium receipts, investment assets, working capital, and regulated capital needs all matter. For Elevance Health, the key question is whether liquidity can cover obligations without pressuring operations or growth, and the latest balance sheet suggests useful capacity but not unlimited freedom. See Elevance Health Inc. (ELV): History, Ownership, Mission, How It Works & Makes Money.
| Area | Latest Evidence | Assessment | Investor Meaning |
|---|---|---|---|
| Cash and Working Capital | As of 2026-03-31, Cash And Cash Equivalents were $966B, Short Term Investments were $2591B, Cash And Short Term Investments were $3556B, Net Receivables were $2279B, Other Current Assets were $868B, Total Current Assets were $6703B, and Total Current Liabilities were $4531B; Days in Claims Payable was 466 days, up from 413 days at year-end 2025. | Strong | Near-term obligations look manageable, but claims timing still needs close monitoring. |
| Total and Net Debt | Long Term Debt was $3112B, Short Term Debt was $72400M, and Total Debt was $3184B on 2026-03-31; Cash And Cash Equivalents were $966B and Cash And Short Term Investments were $3556B. | Mixed | Debt is meaningful, so flexibility is useful but not unlimited. |
| Debt Service and Refinancing | Interest Expense was $35700M for 2026-03-31, and Debt Growth was -419% for 2026-03-31 after 353% for 2025-12-31. | Mixed | Debt service is visible, but the company still needs stable access to capital and operating cash flow. |
| Asset Quality | Total Assets were $12583B, Property Plant Equipment Net was $466B, Goodwill was $2834B, Intangible Assets were $1109B, and Goodwill And Intangible Assets were $3943B. | Mixed | Acquisition-related assets add scale, but they need monitoring for impairment if performance weakens. |
| Liabilities and Equity | Total Current Liabilities were $4531B, Total Payables were $621B, Deferred Revenue was $176B, Other Current Liabilities were $3662B, and the supplied $935M CMS accrual could reduce liquidity if paid. | Mixed | The liability base is sizable, so equity and liquidity together must absorb operating and regulatory pressure. |
What balance-sheet risk matters most for Elevance Health?
Working-capital and claims-liability timing is the biggest watch item, because insurer liquidity can shift quickly even when cash and short-term investments look large.
- Current Exposure: Days in Claims Payable was 466 days, up from 413 days at year-end 2025.
- Protection: Cash And Cash Equivalents were $966B and Cash And Short Term Investments were $3556B.
- Warning Signal: Watch whether claims timing, debt use, or the CMS accrual starts to reduce liquidity flexibility.
Mixed efficiency
Is Elevance Health using capital efficiently while funding growth?
Mixed. Elevance Health appears to fund shareholder returns and reinvestment from ongoing earnings, but internal cash is not fully verifiable from the supplied data, so capital efficiency looks adequate but not clearly strong.
Return quality should be read with leverage, asset intensity, capital spending, working capital, and outside funding needs. For Elevance Health, buybacks, dividends, Carelon investment, and acquisition activity matter more than a single ratio because they show how cash is split between shareholders and growth. See Elevance Health Inc. (ELV): History, Ownership, Mission, How It Works & Makes Money.
| Capital Measure | Latest Evidence | Quality Test | Investor Meaning |
|---|---|---|---|
| ROIC | Unavailable in the supplied data for 2026-03-31. | Carelon revenue growth of 790% was offset by an operating gain decline of 380%, which points to uneven capital efficiency. | Invested capital is being deployed, but operating value creation is not yet clearly proven from the provided numbers. |
| ROE and ROA | Net Income was $1.76B for 2026-03-31; ROE and ROA were not supplied. | Share repurchases reduced weighted average shares by -0.59% and diluted shares by -0.63%, which can lift per-share results without changing underlying asset productivity. | Shareholder returns may look better per share, but leverage and asset use still need verification before calling returns high quality. |
| Maintenance and Growth Investment | Elevance Health budgeted several hundred million dollars for 2026 AI capabilities and Medicare Advantage star ratings, and invested in Sydney Health plus Carelon Services and CarelonRx. | Growth spending is visible in care delivery, pharmacy, data, and digital tools, while acquisitions and integration add more capital use. | The company needs ongoing investment to sustain growth, not just maintain the existing base. |
| Internal Funding Capacity | Q1 2026 share repurchases were 37M shares for $1.1B; remaining board-approved repurchase authorization was $5.6B; total capital returned in 2025 was $4.1B. | Funding looks partly internal because earnings support payouts, but the provided data does not include disclosed cash flow dollars. | Elevance Health appears able to fund returns now, yet continued payouts depend on recurring cash after medical costs, CMS exposure, capex, and Carelon investment. |
Are Elevance Health's returns on capital sustainable?
Probably mixed. Carelon, digital, and government-program investments support durability, but the weakest condition is rising reinvestment needs that outpace recurring cash after medical costs and CMS-related pressure.
- Operating Source: Carelon scale, digital tools, and payer-services mix support returns.
- Funding Requirement: The largest verified capital needs are buybacks, dividends, and Carelon investment.
- Durability Test: Returns weaken if operating gain, cash generation, or share-count reduction slows while reinvestment stays high.
Financial Resilience
What could weaken Elevance Health's financial resilience?
Elevance Health looks Mixed. The main buffer is its large, diversified health benefits and Carelon platform, but the most important verified warning sign is medical cost pressure, with the Benefit Expense Ratio at 86.80% in Q1 2026 and 90.00% for full year 2025.
Elevance Health can still cover debt service and essential investment, but resilience weakens if medical trends stay above pricing, government-program margins miss recovery, or regulatory costs rise. That is why the company’s own 2026 execution focus matters, and why the recent CMS-related issue and the Exploring Elevance Health Inc. (ELV) Investor Profile: Who's Buying and Why? context both matter for investors tracking sentiment and risk.
| Pressure | Financial Effect | Existing Protection | Warning Signal |
|---|---|---|---|
| Revenue or Margin Pressure | Higher medical costs compress operating leverage, reduce earnings and cash flow, and can limit debt capacity if premium yield and benefit design do not keep pace. | Recurring health benefits demand, higher premium yields, disciplined Medicare Advantage plan exits, and benefit redesigns. | Rising Benefit Expense Ratio, lower Health Benefits operating gain, or weaker government-program margins. |
| Working-Capital or Investment Pressure | Claims timing and investment needs can absorb cash, especially if receivables or reserves rise faster than operating cash flow. | Internal funding capacity and a claims-paying model that usually converts premium collections into future payments. | Falling operating cash flow, faster asset growth, or continued pressure in Days in Claims Payable from 466 days. |
| Interest or Refinancing Pressure | Higher interest costs or refinancing strain would reduce free cash flow and limit flexibility if earnings weaken further. | Scale, diversified earnings, and management’s focus on execution rather than balance-sheet stress. | Lower GAAP EPS guidance, a worsening CMS accrual, or signs that liquidity is being used faster than expected. |
Which financial warning signs should investors monitor at Elevance Health?
Monitor medical cost trends first, then the CMS accrual and GAAP EPS guidance, and finally membership mix. The current deterioration is already visible in margins and guidance; the future risk is a larger membership shift away from Medicaid and Medicare Advantage.
Medical cost pressure is still the top risk
Elevance Health posted a Benefit Expense Ratio of 86.80% in Q1 2026 and 90.00% for full year 2025, while Medicaid margins were expected to decline by at least 125 basis points in 2026. Watch the next Benefit Expense Ratio and Health Benefits operating gain.
CMS exposure can hit earnings and flexibility
Elevance Health recorded a $935M accrual tied to potential CMS exposure, and regulators warned of sanctions, including a possible halt on new MA enrollment. The key checks are updated CMS disclosure, accrual changes, and whether Full Year 2026 GAAP Diluted EPS guidance stays at least $19.85.
Membership mix may weaken scale economics
Total medical membership was 45.4M, with Medicare Advantage enrollment at 1.9M members and Medicaid membership at 8.5M, with an anticipated loss of 750K Medicaid members in 2026. Track medical membership by line of business for signs of mix pressure.
Financial Scorecard
What does Elevance Health's financial health mean for investors?
Elevance Health scores Mixed. The strongest factor is liquidity backed by large healthcare scale and Carelon growth. The weakest factor is government-program margin and regulatory pressure. The most important condition for the investment case is whether adjusted earnings can turn into durable GAAP earnings and cash.
| Financial Factor | Rating | Evidence and Investor Meaning |
|---|---|---|
| Revenue and Earnings Quality | Mixed | Full Year 2025 Operating Revenue of $1976B and Q1 2026 Operating Revenue of $495B show scale, and Carelon helps growth, but Full Year 2025 GAAP Net Income of $57B and government-program mix pressure weaken quality. |
| Profitability and Cash | Mixed | Q1 2026 Net Income of $176B and FMP Operating Cash Flow Growth of 505714% are positive, but Benefit Expense Ratio of 8680%, Medicaid pressure, and no disclosed FCF dollars limit confidence. |
| Balance Sheet and Liquidity | Strong | Cash And Short Term Investments of $3556B and Total Current Assets of $6703B support flexibility, though Total Debt of $3184B, Long Term Debt of $3112B, and $35700M of interest expense still matter. |
| Capital Efficiency | Mixed | Total capital returned to shareholders in 2025 of $41B, Q1 2026 repurchases of 37M shares for $11B, and a $56B authorization show support, but Carelon and AI spending raise reinvestment needs. |
| Financial Resilience | Mixed | Scale, Blue Cross Blue Shield branded coverage in 14 states, Carelon diversification, and liquidity help, but Medicaid margin pressure, Medicare Advantage enrollment decline, CMS exposure, and claims payable movement remain key risks. |
- What Supports the Thesis: Durable revenue, Carelon scaling, and heavy capital returns support the case for stability and cash generation.
- What Challenges the Thesis: Government-program margin pressure and uncertainty around adjusted earnings converting into durable GAAP earnings and cash.
- What to Monitor: Benefit Expense Ratio, Days in Claims Payable, Full Year 2026 GAAP Diluted EPS guidance.
For students using Elevance Health Inc. (ELV): History, Ownership, Mission, How It Works & Makes Money, this scorecard also fits forecasts, scenarios, and valuation work because the key question is whether scale and liquidity can offset margin pressure.
FAQ
What Do Investors Ask About 's Financial Health?
Investors most often ask about the company's revenue quality, profitability, cash generation, debt, liquidity, capital efficiency, and ability to withstand financial pressure.
Why did Elevance Health's benefit expense ratio rise?
The benefit expense ratio rose because medical cost pressure remained elevated, especially in Medicaid Q1 2026 Benefit Expense Ratio was 8680%, up 40 basis points from Q1 2025 Full Year 2025 Benefit Expense Ratio was 9000%, up 150 basis points from 2024
What drives Elevance Health's cash conversion?
Cash conversion depends on premium collections, claims payments, working capital, investment timing, and capex FMP shows Operating Cash Flow Growth of 505714% and Free Cash Flow Growth of 206029% for 2026-03-31, but no cash flow dollar values were provided
How should investors read ELV debt levels?
Use balance-sheet and enterprise-value debt data, not market value At 2026-03-31, Elevance Health had Short Term Debt of $72400M, Long Term Debt of $3112B, and Total Debt of $3184B, alongside Cash And Short Term Investments of $3556B
Can payouts continue while Carelon absorbs investment?
Elevance Health continued payouts with Q1 2026 repurchases of 37M shares for $11B and a quarterly dividend of $172 per share Sustainability depends on recurring cash flow after medical costs, CMS exposure, AI investment, Carelon expansion, and working-capital needs
Which resilience metrics deserve closest monitoring?
Investors should monitor Benefit Expense Ratio, Days in Claims Payable, and GAAP EPS guidance These show whether medical costs, claims timing, and CMS-related exposure are improving or worsening They also connect operating pressure to liquidity, earnings quality, and capital allocation flexibility